← Back

Pharma Reaserch Prod Co Ltd

PharmaResearch Co., Ltd. is a biopharmaceutical company based in South Korea that operates with its subsidiaries. It offers a range of products including Re-An eye drops, JBP PLAMON injection, ZADAXIN injection, PLACENTEX injection, CLEVIEL VOLUME, Rejuran HB plus, Rejuvenex injection, and Rejuvenex cream. The company also provides medical devices such as REJURAN, CLEVIEL prime plus and contour plus with lidocaine, D+CELL 350 TRA I, and REJURAN moisturizer, as well as REJUVENEX SCULPT V, REJURAN concentrate, REJURAN healing eye gel and mask, REJURAN sunscreen, and REJURAN recover soothing mask. Additionally, it offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. The company also provides functional foods and engages in software development and consulting businesses. Formerly known as Pharma Research Products Co., Ltd., it changed its name to PharmaResearch Co., Ltd. in April 2021. Founded in 1993, it is headquartered in Gangneung-si, South Korea.

Country
Price · split & dividend adjusted
News & notes moving 214450.KQ
214450.KQ

PharmaResearch to Acquire CG USA to Boost REJURAN Cosmetics in Americas

PharmaResearch has signed an agreement to acquire Cosmetic Group USA, a California-based cosmetics manufacturer, to strengthen local production and logistics for its REJURAN Cosmetics brand across North and South America. The acquisition of CG USA, which operates an FDA-registered facility with cGMP-aligned quality systems and over-the-counter production capabilities, will allow PharmaResearch to shift from supplying the U.S. market with Korean-made products to local manufacturing. The move aims to improve supply chain efficiency and market responsiveness as REJURAN Cosmetics expands through Sephora, Amazon, and a planned entry into Canada in the second half of the year. CEO Ji Hoon Sohn said the deal secures a local production base to support growth in North America and opens potential for expanding the company's ODM business in the U.S. over the mid to long term. Financial terms were not disclosed.
PR Newswire·80dRead more →